—that is not in the spirit of any kind of transparency and full disclosure that anyone would expect in the field or that was promised and indicated to me was a commitment that was fulfilled by the head of this program and leading scientists at the laboratory in Winnipeg.
Let me go on further to Kirsty Duncan's questioning around the study that has been used as one of the excuses for the termination of these bids. Are you aware of a study that has been done to critique the Gates study? I want to refer specifically to a study done by Don Gerson, who is a leading expert in this field. He has his Ph.D. from McGill, he is a professor of biophysics and biochemical engineering at the University of Western Ontario, he is president and CEO of PnuVax, Inc., and he did, on March 8, a complete analysis of the Gates study, indicating in fact that “this study is fatally flawed by its failure to place priority on the quality aspects of clinical materials manufacturing”.
Are you aware of the importance of good manufacturing practices and what that means in this context?